Advertisement

A Comparison of Regorafenib and TAS-102 for Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis

Published:November 02, 2017DOI:https://doi.org/10.1016/j.clcc.2017.10.016

      Abstract

      Background

      Regorafenib and TAS-102 have shown to be superior to placebo in refractory metastatic colorectal cancer. However, no studies have directly compared both drugs. Giving the lack of standard options in this scenario, a systematic review to compare the efficacy and safety of regorafenib and TAS-102 was performed.

      Materials and Methods

      A systematic review using the PubMed, Medline, Embase, Scopus, and Cochrane databases to identify published and unpublished studies up to November 2015 for randomized controlled trials for patients with metastatic colorectal cancer, involving regorafenib or TAS-102, was performed. Data including overall survival, progression-free survival, and toxicity were extracted. Pairwise direct meta-analyses (regorafenib vs. placebo and TAS-102 vs. placebo) and indirect comparison (regorafenib vs. TAS-102) using network meta-analyses methods to preserve randomization were performed using random effects.

      Results

      Three randomized controlled trials fulfilled eligibility criteria (regorafenib monotherapy for previously treated metastatic colorectal cancer [CORRECT]: an international, multicentre, randomised, pacebo-controlled, phase 3 trial, regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer [CONCUR]: a randomised, double-blind, placebo-controlled, phase 3 trial, and randomized trial of TAS-102 for refractory metastatic colorectal cancer [RECOURSE] trials) involving 1764 patients (regorafenib, 641; TAS-102, 534; placebo, 589). Subgroups of patients (1659) who had not received prior regorafenib or TAS-102 were used to perform meta-analyses for efficacy. In the indirect comparison, no statistically significant differences were observed between regorafenib and TAS-102 in overall survival (hazard ratio, 0.96; 95% confidence interval [CI], 0.57-1.66; P = .91) or progression-free survival (hazard ratio, 0.85; 95% CI, 0.40-1.81; P = .67). However, regorafenib has statistically more all grade any toxicity (risk difference, 0.31; 95% CI, 0.25-0.38; P = .001) compared with TAS-102. Subgroup analysis of adverse events showed a different toxicity profile between both drugs.

      Conclusion

      In this indirect comparison, regorafenib and TAS-102 appeared to have similar efficacy. However, regorafenib was associated with more toxicity compared with TAS-102.

      Keywords

      To read this article in full you will need to make a payment

      Subscribe:

      Subscribe to Clinical Colorectal Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ferlay J.
        • Shin H.-R.
        • Bray F.
        • Forman D.
        • Mathers C.
        • Parkin D.M.
        Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
        Int J Cancer. 2010; 127: 2893-2917
        • Fakih M.G.
        Metastatic colorectal cancer: current state and future directions.
        J Clin Oncol. 2015; 33: 1809-1824
        • Van Cutsem E.
        • Nordlinger B.
        • Cervantes A.
        • ESMO Guidelines Working Group
        Advanced colorectal cancer: ESMO Clinical Practice Guidelines for treatment.
        Ann Oncol. 2010; 21 Suppl 5: v93-v97
        • Goldberg R.M.
        • Sargent D.J.
        • Morton R.F.
        • et al.
        A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.
        J Clin Oncol. 2004; 22: 23-30
        • de Gramont A.
        • Figer A.
        • Seymour M.
        • et al.
        Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.
        J Clin Oncol. 2000; 18: 2938-2947
        • Falcone A.
        • Ricci S.
        • Brunetti I.
        • et al.
        Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
        J Clin Oncol. 2007; 25: 1670-1676
        • Cassidy J.
        • Clarke S.
        • Diaz-Rubio E.
        • et al.
        Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
        J Clin Oncol. 2008; 26: 2006-2012
        • Hurwitz H.
        • Fehrenbacher L.
        • Novotny W.
        Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
        N Engl J Med. 2004; 350: 2335-2342
        • Van Cutsem E.
        • Köhne C.-H.
        • Hitre E.
        • et al.
        Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.
        N Engl J Med. 2009; 360: 1408-1417
        • Douillard J.-Y.
        • Siena S.
        • Cassidy J.
        • et al.
        Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.
        J Clin Oncol. 2010; 28: 4697-4705
        • Sanz-Garcia E.
        • Grasselli J.
        • Argiles G.
        • Elez M.E.
        • Tabernero J.
        Current and advancing treatments for metastatic colorectal cancer.
        Expert Opin Biol Ther. 2016; 16: 93-110
        • Wilhelm S.M.
        • Dumas J.
        • Adnane L.
        • et al.
        Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
        Int J Cancer. 2011; 129: 245-255
        • Grothey A.
        • Van Cutsem E.
        • Sobrero A.
        • et al.
        Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
        Lancet. 2013; 381: 303-312
        • Li J.
        • Qin S.
        • Xu R.
        • et al.
        Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.
        Lancet Oncol. 2015; 16: 619-629
        • Lenz H.-J.
        • Stintzing S.
        • Loupakis F.
        TAS-102, a novel antitumor agent: a review of the mechanism of action.
        Cancer Treat Rev. 2015; 41: 777-783
        • Yoshino T.
        New drug development for refractory metastatic colorectal cancer in Japan.
        Ann Oncol. 2014; 25: v23
        • Zaniboni A.
        • Bertocchi P.
        • Barni S.
        • Petrelli F.
        TAS-102 (Lonsurf) for the treatment of metastatic colorectal cancer. A concise review.
        Clin Colorectal Cancer. 2016; 15: 292-297
        • Mayer R.J.
        • Van Cutsem E.
        • Falcone A.
        • et al.
        Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
        N Engl J Med. 2015; 372: 1909-1919
        • Strumberg D.
        • Scheulen M.E.
        • Schultheis B.
        • et al.
        Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
        Br J Cancer. 2012; 106: 1722-1727
        • Mross K.
        • Frost A.
        • Steinbild S.
        • et al.
        A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
        Clin Cancer Res. 2012; 18: 2658-2667
        • Bendell J.C.
        • Rosen L.S.
        • Mayer R.J.
        • et al.
        Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
        Cancer Chemother Pharmacol. 2015; 76: 925-932
        • Doi T.
        • Ohtsu A.
        • Yoshino T.
        • et al.
        Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours.
        Br J Cancer. 2012; 107: 429-434
        • Sueda T.
        • Sakai D.
        • Kudo T.
        • et al.
        Efficacy and safety of regorafenib or TAS-102 in patients with metastatic colorectal cancer refractory to standard therapies.
        Anticancer Res. 2016; 36: 4299-4306
        • Masuishi T.
        • Taniguchi H.
        • Hamauchi S.
        • et al.
        Regorafenib versus trifluridine/tipiracil for refractory metastatic colorectal cancer: a retrospective comparison.
        Clin Colorectal Cancer. 2017; 16: e15-e22
        • Parmar M.K.
        • Torri V.
        • Stewart L.
        Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.
        Stat Med. 1998; 17: 2815-2834
      1. (Version 5.1)Review Manager (RevMan) [Computer program]. The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen2014
        • Salanti G.
        • Higgins J.P.T.
        • Ades A.E.
        • Ioannidis J.P.A.
        Evaluation of networks of randomized trials.
        Stat Methods Med Res. 2008; 17: 279-301
        • Caldwell D.M.
        • Ades A.E.
        • Higgins J.P.T.
        Simultaneous comparison of multiple treatments: combining direct and indirect evidence.
        BMJ. 2005; 331: 897-900
        • Rücker G.
        • Schwarzer G.
        Automated drawing of network plots in network meta-analysis.
        Res Synth Methods. 2015; 7: 94-107
        • Neupane B.
        • Richer D.
        • Bonner A.J.
        • Kibret T.
        • Beyene J.
        Network meta-analysis using R: a review of currently available automated packages.
        PLoS One. 2014; 9: e115065
        • Kim T.W.
        • Shen L.
        • Xu J.M.
        • Sriuranpong V.
        TERRA: a randomized, double- blind, placebo-controlled phase 3 study of TAS-102 in Asian patients with metastatic colorectal cancer.
        Ann Oncol. 2016; 27: 149-206
        • Moriwaki T.
        • Fukuoka S.
        • Taniguchi H.
        • et al.
        Propensity score analysis of regorafenib versus trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to standard chemotherapy (REGOTAS): a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
        Oncologist. 2017; https://doi.org/10.1634/theoncologist.2017-0275
        • Arita S.
        • Shirakawa T.
        • Matsushita Y.
        • et al.
        Efficacy and safety of TAS-102 in clinical practice of salvage chemotherapy for metastatic colorectal cancer.
        Anticancer Res. 2016; 36: 1959-1966